SITC 2021 | Improving patient-reported outcomes in NSCLC

Eric K. Singhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, emphasizes the importance of improving the experience of patients with metastatic non-small cell lung cancer (NSCLC). For instance, by identifying toxicities earlier in the treatment course and having clinically meaningful interventions. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.